News

Semaglutide Before Surgery: Do You Need to Stop?

Creator: Julian Reyes, Health Writer
Published: 2026-09-01

Most patients can continue semaglutide before an elective procedure, but the plan changes when delayed stomach emptying is more likely. The anesthesia and prescribing teams should make that call together.

Julian Reyes, Health Writer September 1, 2026 5 min read

Two adults in modest knitwear talk beside a sunlit living room window

The short version

October 2024 multi-society guidance says most low-risk patients can continue GLP-1 treatment before elective surgery; the June 2023 advice had called for holding weekly drugs for seven days and daily drugs on procedure day.
Dose escalation, current nausea or vomiting, abdominal pain, bloating, constipation, higher doses and another cause of slow stomach emptying can move a patient into a higher-risk plan.
A 24-hour liquid-only diet, gastric ultrasound, an aspiration-conscious anesthesia plan or a short delay are options the care team may use instead of an automatic medication hold.
In a 2024 prospective study, increased residual stomach contents appeared in 40% of recent semaglutide users versus 3% of controls, but no aspiration occurred in the study.
Semaglutide's half-life is about one week, so five half-lives leave roughly 3%; that five-week washout arithmetic is not the current routine preoperative rule.

Most people do not need to stop semaglutide before surgery under the October 2024 multi-society guidance. The older June 2023 advice said to hold weekly GLP-1 drugs for seven days, but the update shifted to individual risk. People without elevated risk can usually continue, while the care team may use a 24-hour liquid-only diet, stomach ultrasound, a different anesthesia plan or a delay for higher-risk elective cases. Tell both the anesthesia team and the semaglutide prescriber the exact product, dose, last injection date and any digestive symptoms.

Why anesthesia teams care about a full stomach

Semaglutide can slow gastric emptying: food and fluid may remain in the stomach longer. Under general anesthesia or deep sedation, protective airway reflexes are reduced. Stomach contents that come back up can enter the lungs, an event called pulmonary aspiration. That is why ordinary fasting instructions matter and why a medication that changes stomach emptying gets extra attention.

The concern began with a small number of clinical reports, not a large trial. In one 2023 case report, a patient who had started weekly semaglutide two months earlier had substantial stomach contents after an 18-hour fast and aspirated during an endoscopic procedure. A case report can identify a plausible hazard, but it cannot show how often that hazard occurs.

Semaglutide before surgery: what changed in 2024

The American Society of Anesthesiologists' June 2023 guidance took a simple approach for elective procedures: hold a daily GLP-1 medicine on the day of the procedure and a weekly one for seven days. The advice applied regardless of dose or reason for treatment. It also said that urgent and emergency procedures should be managed as if the stomach were full.

On October 29, 2024, ASA joined gastroenterology, bariatric-surgery and perioperative-care societies in new clinical guidance. Most people at low risk for delayed stomach emptying could continue their GLP-1 medicine. For higher-risk patients, the team could consider a liquid-only diet for at least 24 hours, point-of-care gastric ultrasound, an anesthesia technique that protects against aspiration, or deferring an elective procedure until the temporary risk settles.

The shift was not a declaration that retained food does not matter. It recognized that risk differs from person to person and that pausing treatment has tradeoffs, including loss of glucose control for someone using semaglutide for type 2 diabetes. As of August 2026, there is no single stop interval that fits every patient, procedure and facility. Local protocols may therefore differ.

Who may need a more cautious plan

The 2024 guidance highlights several reasons for extra caution:

Dose escalation. Delayed stomach emptying is more likely while treatment is beginning and the dose is being increased.
Current digestive symptoms. Nausea, vomiting, abdominal pain, bloating or constipation can signal slower stomach emptying. Our semaglutide side-effects guide covers those effects in more detail.
Higher doses. Gastrointestinal effects tend to be more common as exposure rises.
Another condition that slows the stomach. Gastroparesis and neurologic disorders such as Parkinson's disease can change the calculation.
The procedure and anesthesia plan. Deep sedation, general anesthesia and a procedure involving the upper digestive tract do not present the same choices.

The issue is class-wide, not unique to one semaglutide brand. Tirzepatide has GLP-1 activity and is also used as a weekly injection, so its name and last-dose date belong in the same preoperative medication review. Its persistence is explained separately in how long tirzepatide stays in the body.

What the evidence can and cannot prove

Gastric ultrasound gives the clearest signal. In a JAMA Surgery 2024 study of 124 fasted patients, increased residual stomach contents appeared in 56% of GLP-1 users and 19% of nonusers. A separate 2024 prospective study of 220 surgical patients found increased contents in 43 of 107 recent semaglutide users, or 40%, versus 3 of 113 controls, or 3%. No aspiration occurred in that study.

Those results show that standard fasting does not guarantee an empty stomach for every GLP-1 user. They do not establish that 40% or 56% of users will aspirate. Retained contents are a risk marker; aspiration is a much rarer clinical event.

That distinction is supported by later outcomes research. A JAMA Network Open 2025 cohort included 366,476 people having 14 common operations. After adjustment, a preoperative GLP-1 prescription was not associated with significantly higher odds of aspiration pneumonia. The study used insurance claims and could not capture the last dose, fasting duration, gastric-ultrasound result or anesthesia precautions, so it does not close the question. It does explain why current guidance favors individual risk assessment over automatic cancellation.

Five weeks is washout math, not a universal deadline

Semaglutide's elimination half-life is about one week. After one half-life, roughly half remains; after five, roughly 3% remains. That is the source of the often-quoted five-week washout estimate, and how long semaglutide stays in the body walks through the arithmetic.

The number does not mean every patient should pause for five weeks. Drug remaining in the bloodstream is not the same measurement as food remaining in the stomach, and the guidance does not set five weeks as a routine surgical hold. A long pause can also affect glucose management, appetite and access to treatment. Whether semaglutide is continued or paused is a decision for the patient, prescribing clinician, surgeon and anesthesia professional together.

What the care team needs to know

The useful preoperative facts are concrete: semaglutide's exact formulation, whether it is injected or oral, the dose, the last dose date, whether the dose recently changed, why it is prescribed and whether nausea, vomiting, bloating, abdominal pain, constipation or an inability to tolerate food is present. That conversation should happen before the procedure day when possible.

At Promise, a licensed provider reviews every request, and not everyone qualifies. If surgery is scheduled after prescribing, the Promise clinician can help the procedure team understand the treatment record, while the anesthesiologist makes the final anesthesia-day assessment. A facility's fasting instructions still control; a liquid-only plan is a clinical instruction from that team, not a do-it-yourself substitute for ordinary fasting rules.

Common questions

How long should semaglutide be stopped before surgery?

There is no universal stop interval. The October 2024 multi-society guidance says most low-risk patients can continue semaglutide before elective surgery. A clinician may consider a pause or other precautions when a patient is increasing the dose, has digestive symptoms, takes a higher dose or has another cause of delayed stomach emptying. The anesthesia and prescribing teams set the individual plan.

Can semaglutide be taken the week before surgery?

Often, yes. Current multi-society guidance no longer uses a blanket seven-day hold for everyone taking a weekly GLP-1 medicine. The answer depends on digestive symptoms, dose escalation, other conditions that slow stomach emptying, the type of procedure and the planned anesthesia. The surgical facility may also follow a more conservative local protocol, so its instructions take priority.

Why can semaglutide affect anesthesia?

Semaglutide can delay stomach emptying. If food or fluid remains when protective airway reflexes are reduced by general anesthesia or deep sedation, it can come back up and enter the lungs. Studies have found more residual stomach contents in fasted GLP-1 users, although large observational studies have not established a corresponding increase in aspiration pneumonia after surgery.

Does semaglutide stay in the body for five weeks?

A small amount can remain after five weeks because semaglutide's half-life is about one week. Five half-lives leave roughly 3% of the starting amount. That washout arithmetic is not a recommendation to stop for five weeks before every procedure. Bloodstream concentration and stomach contents are different measurements, so the clinical plan depends on individual aspiration and metabolic risks.

What happens if stomach symptoms start before surgery?

The procedure team should know promptly, especially about vomiting, persistent nausea, abdominal pain, marked bloating, constipation or an inability to tolerate food. Symptoms can change the plan even when ordinary fasting instructions were followed. The team may consider a delay, gastric ultrasound, a liquid-only period or a different anesthesia approach; the appropriate choice depends on the patient and procedure.

Does the surgery guidance also apply to tirzepatide?

Yes. The multi-society guidance covers GLP-1 receptor agonists and related medicines, including tirzepatide, which has both GIP and GLP-1 activity. Anyone taking tirzepatide should include its exact product, dose and last injection date in the preoperative medication review. The anesthesia and prescribing teams then weigh digestive symptoms, dose changes, other conditions and the planned procedure.